Literature DB >> 20547629

Myasthenia and related disorders of the neuromuscular junction.

Jennifer Spillane1, David J Beeson, Dimitri M Kullmann.   

Abstract

Our understanding of transmission at the neuromuscular junction has increased greatly in recent years. We now recognise a wide variety of autoimmune and genetic diseases that affect this specialised synapse, causing muscle weakness and fatigue. These disorders greatly affect quality of life and rarely can be fatal. Myasthenia gravis is the most common disorder and is most commonly caused by autoantibodies targeting postsynaptic acetylcholine receptors. Antibodies to muscle-specific kinase (MuSK) are detected in a variable proportion of the remainder. Treatment is symptomatic and immunomodulatory. Lambert-Eaton myasthenic syndrome is caused by antibodies to presynaptic calcium channels, and approximately 50% of cases are paraneoplastic, most often related to small cell carcinoma of the lung. Botulism is an acquired disorder caused by neurotoxins produced by Clostridium botulinum, impairing acetylcholine release into the synaptic cleft. In addition, several rare congenital myasthenic syndromes have been identified, caused by inherited defects in presynaptic, synaptic basal lamina and postsynaptic proteins necessary for neuromuscular transmission. This review focuses on recent advances in the diagnosis and treatment of these disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547629     DOI: 10.1136/jnnp.2008.169367

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

Review 1.  Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS.

Authors:  Sanjeev Rajakulendran; Diego Kaski; Michael G Hanna
Journal:  Nat Rev Neurol       Date:  2012-01-17       Impact factor: 42.937

Review 2.  Pediatric Paroxysmal Exercise-Induced Neurological Symptoms: Clinical Spectrum and Diagnostic Algorithm.

Authors:  Federica Rachele Danti; Federica Invernizzi; Isabella Moroni; Barbara Garavaglia; Nardo Nardocci; Giovanna Zorzi
Journal:  Front Neurol       Date:  2021-06-01       Impact factor: 4.003

3.  Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies.

Authors:  Giovanna Cenacchi; Valentina Papa; Papa Valentina; Marina Fanin; Fanin Marina; Elena Pegoraro; Pegoraro Elena; Corrado Angelini; Angelini Corrado
Journal:  J Neurol       Date:  2010-11-19       Impact factor: 4.849

4.  Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy.

Authors:  Nils Erik Gilhus
Journal:  Autoimmune Dis       Date:  2011-09-29

5.  Super-Resolution Microscopy Reveals a Nanoscale Organization of Acetylcholine Receptors for Trans-Synaptic Alignment at Neuromuscular Synapses.

Authors:  Amanda L York; James Q Zheng
Journal:  eNeuro       Date:  2017-08-10

6.  Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients.

Authors:  Carl Johan Molin; Elisabet Westerberg; Anna Rostedt Punga
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

7.  Morphological analysis of neuromuscular junction development and degeneration in rodent lumbrical muscles.

Authors:  James N Sleigh; Robert W Burgess; Thomas H Gillingwater; M Zameel Cader
Journal:  J Neurosci Methods       Date:  2014-02-14       Impact factor: 2.390

8.  Two patients with a neuroendocrine tumour of the small intestine and paraneoplastic myasthenia gravis.

Authors:  M A W Hermans; B M L Stelten; H R Haak; W W de Herder; M W Dercksen
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-05-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.